title: Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
abstract: BACKGROUND
  The lowering of cholesterol concentrations in individuals at high risk for cardiovascular disease improves clinical outcome. Xuezhikang has a marked impact on lipids.
  
  
  METHODS
  In this randomized, double-blinded, placebo-controlled, parallel-group clinical trial, a total of 2704 hypertensive patients with previous myocardial infarction (MI) were assigned either to placebo (n = 1341) or to Xuezhikang (0.6 g twice daily, n = 1363) for an average of 4.5 years. The primary end-point was recurrent coronary events; the secondary end-point was all-cause mortality and other clinical events, including adverse effects.
  
  
  RESULTS
  There were no differences between the Xuezhikang and placebo group in base-line characteristics. However, Xuezhikang treatment reduced the incidence of coronary events by 43.0% (P = 0.02), deaths from coronary heart disease (CHD) by 30.0% (P < 0.01), and all-cause mortality by 35.8% (P = 0.001).
  
  
  CONCLUSIONS
  This study, for the first time, demonstrated that long-term Xuezhikang therapy resulted in significant reduction in cardiovascular events and death in Chinese hypertensive patients with previous MI in a safe manner.
authors.affiliation: Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P. R. China. lijnjn@yahoo.com.cn
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Zong-Liang
authors.initials: ZL
authors.lastname: Lu
authors.forename: Wen-Rong
authors.initials: WR
authors.lastname: Kou
authors.forename: Zuo
authors.initials: Z
authors.lastname: Chen
authors.forename: Yang-Feng
authors.initials: YF
authors.lastname: Wu
authors.forename: Xue-Hai
authors.initials: XH
authors.lastname: Yu
authors.forename: Yu-Cheng
authors.initials: YC
authors.lastname: Zhao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002681:China / Q000453:epidemiology; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000178:diet therapy* / Q000401:mortality; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D055815:Young Adult
chemical_list: D004365:Drugs, Chinese Herbal; D008074:Lipoproteins; C496822:xuezhikang